Kodiak Sciences, a Phase 1 biotech developing antibody therapies to treat age-related macular degeneration, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
The Palo Alto, CA-based company was founded in 2009 and plans to list on the Nasdaq under the symbol KOD. Kodiak Sciences filed confidentially on February 14, 2018. Morgan Stanley and BofA Merrill Lynch are the joint bookrunners on the deal. No pricing terms were disclosed.
